Viridian Therapeutics Inc (VRDN)

$13.90 -4.94 (-26.22%)
Market Cap 1.93B
Revenue (ttm) 70.85M
Net Income (ttm) -342.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -483.56%
Debt to Equity Ratio 0.07
Volume 14,466,716
Avg Vol 1,793,490
Day's Range N/A - N/A
Shares Out 102.21M
Stochastic %K 16%
Beta 1.16
Analysts Strong Sell
Price Target $37.76

Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 272 4600
Fax: 617 272 4601
Address:
221 Crescent Street, Suite 103A, Waltham, United States
CallMeMyBeer
CallMeMyBeer Apr. 6 at 8:28 PM
$VRDN Not looking good here. Bulls are screwed
0 · Reply
Erect4tech
Erect4tech Apr. 6 at 7:56 PM
$VRDN back to 14 tomorrow easily
0 · Reply
WAJeff
WAJeff Apr. 6 at 7:48 PM
$VRDN Dodged a bullet here
0 · Reply
Evagaminska
Evagaminska Apr. 6 at 7:37 PM
$VRDN I didn’t follow the treatments trials but I am wondering out loud if both trials designations were same with only difference was the drug? It’s happening too often that priority vouchers are mostly going to big pharma and their trials magically end up being better for most part We know FDA can easily influence steps so big pharma gets “better” results in these trials Don’t know if that’s the case here as I am not invested but FDA clown show under Trump makes most biotechs investors wary?
0 · Reply
HamBoneXoXo
HamBoneXoXo Apr. 6 at 7:21 PM
$VRDN The Widow Maker!
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 6 at 6:40 PM
$AMGN $VRDN Viridian under 10$ next
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 6 at 6:39 PM
$VRDN Amgen’s Phase 3 trial met its primary goal, with 77% of patients showing a strong improvement in eye bulging. Stifel analyst Alex Thompson noted the higher proptosis rate but said Viridian’s Elegrobar could better stand out in the market. Elegrobart reduced eye bulging by about 54% with the four-week regimen and 63% with the eight-week regimen. $AMGN …
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 6 at 6:31 PM
$VRDN . The results of the study showed that Amgen's TEPEZZA achieved a higher response rate to proptosis than Viridian's elegrobart
0 · Reply
topstockalerts
topstockalerts Apr. 6 at 6:31 PM
Viridian Therapeutics shares dropped sharply after Amgen announced strong results from a Phase 3 clinical trial for its thyroid eye disease (TED) treatment. The positive data strengthens Amgen’s position in the market and raises concerns about increased competition for Viridian, which is developing its own subcutaneous TED therapy, veligrotug (formerly VRDN-001). Investors reacted negatively as Amgen’s progress could impact Viridian’s future market share and commercial potential, especially in a space where treatment innovation and delivery methods (such as subcutaneous vs. intravenous) are key differentiators. The news highlights how advancements by larger pharmaceutical companies can significantly influence smaller biotech firms' valuations. $VRDN $AMGN
0 · Reply
dddanielek
dddanielek Apr. 6 at 6:13 PM
$VRDN institutions will manipulate at this level.
0 · Reply
Latest News on VRDN
Why Is Viridian Therapeutics Stock Sinking Monday?

Apr 6, 2026, 1:41 PM EDT - 2 hours ago

Why Is Viridian Therapeutics Stock Sinking Monday?

Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.

Apr 6, 2026, 12:10 PM EDT - 4 hours ago

Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.

AMGN

Why Is Viridian Therapeutics Stock Falling Monday?

Mar 30, 2026, 10:01 AM EDT - 7 days ago

Why Is Viridian Therapeutics Stock Falling Monday?

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

Mar 30, 2026, 7:01 AM EDT - 7 days ago

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 7:01 AM EST - 5 weeks ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 8, 2026, 4:01 PM EST - 3 months ago

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Prepares for Transformational 2026

Jan 6, 2026, 7:01 AM EST - 3 months ago

Viridian Therapeutics Prepares for Transformational 2026

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Dec 22, 2025, 7:00 AM EST - 3 months ago

Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

Dec 15, 2025, 10:25 AM EST - 4 months ago

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

ARGX

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 5, 2025, 7:01 AM EST - 5 months ago

Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Nov 3, 2025, 7:01 AM EST - 5 months ago

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Oct 21, 2025, 11:24 PM EDT - 5 months ago

Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Oct 21, 2025, 4:01 PM EDT - 5 months ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Oct 20, 2025, 7:30 AM EDT - 6 months ago

Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

Sep 15, 2025, 7:01 AM EDT - 7 months ago

Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Aug 7, 2025, 2:37 PM EDT - 8 months ago

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 6:30 AM EDT - 8 months ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

Jul 30, 2025, 4:00 AM EDT - 8 months ago

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2025, 7:00 AM EDT - 9 months ago

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

May 30, 2025, 7:00 AM EDT - 11 months ago

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

May 20, 2025, 7:00 AM EDT - 11 months ago

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

May 7, 2025, 4:15 PM EDT - 11 months ago

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 11 months ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Apr 7, 2025, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Jan 8, 2025, 7:00 AM EST - 1 year ago

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Dec 16, 2024, 7:10 AM EST - 1 year ago

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Dec 16, 2024, 7:00 AM EST - 1 year ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Dec 13, 2024, 6:00 PM EST - 1 year ago

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Nov 12, 2024, 7:00 AM EST - 1 year ago

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Sep 11, 2024, 11:25 PM EDT - 1 year ago

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Sep 10, 2024, 4:01 PM EDT - 1 year ago

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Sep 10, 2024, 7:18 AM EDT - 1 year ago

Viridian Therapeutics' eye disorder treatment meets main goal in late-stage study

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Sep 9, 2024, 4:01 PM EDT - 1 year ago

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:15 AM EDT - 1 year ago

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Top 3 Health Care Stocks You May Want To Dump This Quarter

Jul 30, 2024, 10:13 AM EDT - 1 year ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRNA

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Jun 11, 2024, 6:00 AM EDT - 1 year ago

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

May 31, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

May 10, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

May 8, 2024, 7:00 AM EDT - 2 years ago

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

May 7, 2024, 7:33 PM EDT - 2 years ago

Pacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood Village

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 8:00 AM EST - 2 years ago

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 4:01 PM EST - 2 years ago

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Feb 16, 2024, 8:00 AM EST - 2 years ago

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Jan 17, 2024, 10:00 PM EST - 2 years ago

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

Jan 8, 2024, 8:00 AM EST - 2 years ago

Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

CallMeMyBeer
CallMeMyBeer Apr. 6 at 8:28 PM
$VRDN Not looking good here. Bulls are screwed
0 · Reply
Erect4tech
Erect4tech Apr. 6 at 7:56 PM
$VRDN back to 14 tomorrow easily
0 · Reply
WAJeff
WAJeff Apr. 6 at 7:48 PM
$VRDN Dodged a bullet here
0 · Reply
Evagaminska
Evagaminska Apr. 6 at 7:37 PM
$VRDN I didn’t follow the treatments trials but I am wondering out loud if both trials designations were same with only difference was the drug? It’s happening too often that priority vouchers are mostly going to big pharma and their trials magically end up being better for most part We know FDA can easily influence steps so big pharma gets “better” results in these trials Don’t know if that’s the case here as I am not invested but FDA clown show under Trump makes most biotechs investors wary?
0 · Reply
HamBoneXoXo
HamBoneXoXo Apr. 6 at 7:21 PM
$VRDN The Widow Maker!
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 6 at 6:40 PM
$AMGN $VRDN Viridian under 10$ next
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 6 at 6:39 PM
$VRDN Amgen’s Phase 3 trial met its primary goal, with 77% of patients showing a strong improvement in eye bulging. Stifel analyst Alex Thompson noted the higher proptosis rate but said Viridian’s Elegrobar could better stand out in the market. Elegrobart reduced eye bulging by about 54% with the four-week regimen and 63% with the eight-week regimen. $AMGN …
0 · Reply
Messerschmittbf109
Messerschmittbf109 Apr. 6 at 6:31 PM
$VRDN . The results of the study showed that Amgen's TEPEZZA achieved a higher response rate to proptosis than Viridian's elegrobart
0 · Reply
topstockalerts
topstockalerts Apr. 6 at 6:31 PM
Viridian Therapeutics shares dropped sharply after Amgen announced strong results from a Phase 3 clinical trial for its thyroid eye disease (TED) treatment. The positive data strengthens Amgen’s position in the market and raises concerns about increased competition for Viridian, which is developing its own subcutaneous TED therapy, veligrotug (formerly VRDN-001). Investors reacted negatively as Amgen’s progress could impact Viridian’s future market share and commercial potential, especially in a space where treatment innovation and delivery methods (such as subcutaneous vs. intravenous) are key differentiators. The news highlights how advancements by larger pharmaceutical companies can significantly influence smaller biotech firms' valuations. $VRDN $AMGN
0 · Reply
dddanielek
dddanielek Apr. 6 at 6:13 PM
$VRDN institutions will manipulate at this level.
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 6 at 5:45 PM
VRDN Stock Falls To 9-Month Lows – What’s The Amgen Connection? $VRDN $AMGN https://stocktwits.com/news/equity/markets/vrdn-stock-falls-to-nine-month-lows-what-s-the-amgen-connection/cZJ4rAqRIYj
0 · Reply
Tdorsey1776
Tdorsey1776 Apr. 6 at 5:02 PM
$VRDN Stifel analyst Alex Thompson notes that Amgen (AMGN) announced positive topline results for the Phase 3 on-body infusion study of Tepezza achieving a 77% rate of proptosis response, which comes in higher on both an absolute and placebo-adjusted basis compared to Viridian Therapeutics' (VRDN) elegrobar. However, with elegrobart's subcutaneous injection profile versus on-body infusion, the firm sees a path towards differentiation in the market, says the analyst, who has a Buy rating on Viridian shares.
0 · Reply
aliliimr
aliliimr Apr. 6 at 4:18 PM
$VRDN grabbed some at 13.9
1 · Reply
DonCorleone77
DonCorleone77 Apr. 6 at 3:46 PM
$VRDN Viridian sinks after Amgen thyroid eye disease study hits endpoints Shares of Viridian Therapeutics (VRDN) are moving lower after Amgen's (AMGN) Phase 3 trial of Tepezza administered by subcutaneous injection via an on-body injector in participants with moderate-to-severe active thyroid eye disease met the primary and secondary endpoints. Viridian is also developing a treatment for thyroid eye disease.
0 · Reply
notreload_ai
notreload_ai Apr. 6 at 3:23 PM
$VRDN shares fell after $AMGN new, easy Tepezza shot showed strong results for Thyroid Eye Disease. https://notreload.xyz/xy/amgen-tepezza-subq-wins-phase-3-vrdn-drops/
0 · Reply
QuantInsider
QuantInsider Apr. 6 at 3:19 PM
$VRDN is getting hammered after REVEAL-1, down nearly 25% today Traders are piling into short-dated puts like crazy I saw 775 contracts of 4/17 $14 puts swept at the ask, IV around 104 to 110% That makes $14 a key level to watch Options flow over the last 5 days is all puts, 4.1 times normal momentum About $210K in all-sweep premium No sign of dip-buying yet, just heavy downside hedging With VRDN down 28% in 5 days on weak Phase 3 data, it looks like a fundamental hit Any long plays here need tight risk management
0 · Reply
StockBen4444
StockBen4444 Apr. 6 at 3:12 PM
$VRDN now it‘s mine, i see a lot of potential from here first target 23$
0 · Reply
dddanielek
dddanielek Apr. 6 at 3:08 PM
$VRDN what a massacre. Time to reverse?
0 · Reply
Hoopsci
Hoopsci Apr. 6 at 2:34 PM
$VRDN starter here
1 · Reply
TKkamen
TKkamen Apr. 6 at 2:08 PM
$VRDN This is so overdone. Adding to my $28 average position. Small position but this is overdone.
0 · Reply
Cracker36
Cracker36 Apr. 6 at 1:36 PM
$VRDN perfect dip.... im all in here... LFG... 20 eod. 25 eow
1 · Reply
Merlintrader
Merlintrader Apr. 4 at 3:58 PM
$VRDN https://www.merlintrader.com/viridian-therapeutics-after-crash-apr2026/
0 · Reply